This filing is an amendment (Form 10-K/A) to the previously filed 2025 Annual Report. The primary purpose is to provide required information regarding directors, executive officers, corporate governance, and executive compensation that was not included in the original filing. The company confirms it does not intend to file a definitive proxy statement within 120 days of the fiscal year-end. New certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act are included. The filing notes a pending merger agreement with Servier Pharmaceuticals LLC announced on March 6, 2026.